Literature DB >> 11412210

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study.

I Milsom1, P Abrams, L Cardozo, R G Roberts, J Thüroff, A J Wein.   

Abstract

OBJECTIVE: To determine the prevalence of chronic and debilitating symptoms of the overactive bladder, defined here as the presence of chronic frequency, urgency and urge incontinence (either alone or in any combination), and presumed to be caused by involuntary detrusor contractions. Subjects and methods Data were collected using a population-based survey (conducted by telephone or direct interview) of men and women aged >/= 40 years, selected from the general population in France, Germany, Italy, Spain, Sweden and the United Kingdom, using a random stratified approach. The main outcome measures were: prevalence of urinary frequency (> 8 micturitions/24 h), urgency and urge incontinence; the proportion of participants who had sought medical advice for symptoms of an overactive bladder; and current or previous therapy received for these symptoms.
RESULTS: In all, 16 776 interviews were conducted in the six European countries. The overall prevalence of overactive bladder symptoms in individuals aged >/= 40 years was 16.6%. Frequency (85%) was the most commonly reported symptom, followed by urgency (54%) and urge incontinence (36%). The prevalence of overactive bladder symptoms increased with advancing age. Overall, 60% of respondents with symptoms had consulted a doctor but only 27% were currently receiving treatment. Conclusion Symptoms of an overactive bladder, of which frequency and urgency are as bothersome as urge incontinence, are highly prevalent in the general population. However, only a few affected individuals currently receive treatment. Taken together, such findings indicate that there is considerable scope for improvement in terms of how physicians diagnose and treat this condition.

Entities:  

Mesh:

Year:  2001        PMID: 11412210     DOI: 10.1046/j.1464-410x.2001.02228.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  347 in total

1.  Prevalence and predictors of overactive bladder in nonpregnant nulliparous women below 65 years of age.

Authors:  Dudley Robinson; Sigvard Åkervall; Adrian Wagg; Christopher Chapple; Ian Milsom; Maria Gyhagen
Journal:  Int Urogynecol J       Date:  2017-08-04       Impact factor: 2.894

Review 2.  [Use of botulinum toxin type A in non-neurogenic overactive bladder. Recommendations of the Working Group Urological Functional Diagnostics and Urology in Women].

Authors:  R M Bauer; C Seif; T Bschleipfer; A Reitz; D Schultz-Lampel
Journal:  Urologe A       Date:  2015-03       Impact factor: 0.639

Review 3.  Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection.

Authors:  Thomas J Hannan; Makrina Totsika; Kylie J Mansfield; Kate H Moore; Mark A Schembri; Scott J Hultgren
Journal:  FEMS Microbiol Rev       Date:  2012-05       Impact factor: 16.408

4.  M(3) muscarinic receptors mediate contraction of human urinary bladder.

Authors:  Charlotte Fetscher; Marina Fleichman; Martina Schmidt; Susanne Krege; Martin C Michel
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

5.  Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data.

Authors:  Thomas Kerbusch; Peter A Milligan; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

Review 6.  The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy.

Authors:  Karl-Erik Andersson; Nurul Choudhury; Jean-Nicolas Cornu; Moses Huang; Cees Korstanje; Emad Siddiqui; Philip Van Kerrebroeck
Journal:  Ther Adv Urol       Date:  2018-07-06

7.  Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.

Authors:  Sender Herschorn; Jameel Nazir; Barbara Ramos; Zalmai Hakimi
Journal:  Can Urol Assoc J       Date:  2017 Mar-Apr       Impact factor: 1.862

Review 8.  Trospium chloride in the management of overactive bladder.

Authors:  Eric S Rovner
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Review of Economic Value Drivers of the Treatment of Overactive Bladder.

Authors:  Sonya J Snedecor
Journal:  Pharmacoeconomics       Date:  2018-09       Impact factor: 4.981

Review 10.  Female Pelvic Medicine and Reconstructive Surgery-What Does Certification Mean?

Authors:  Steven J Weissbart; Alan J Wein; Ariana L Smith
Journal:  Curr Urol Rep       Date:  2018-03-19       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.